NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM
Delisted
NGM was delisted on the 4th of April, 2024.
51 hedge funds and large institutions have $365M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
51
Holders Change
+3
Holders Change %
+6.25%
% of All Funds
1.12%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
12
Increased
21
Reduced
9
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
PS
Peter Svennilson
|
$224M |
| 2 |
BlackRock
New York
|
$9.06M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
$4.4M |
| 4 |
Northern Trust
Chicago,
Illinois
|
$1.4M |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
$621K |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
EC
51
EcoR1 Capital
San Francisco,
California
| – | -$4.64M | -316,900 | Closed |
|
52
Alyeska Investment Group
Chicago,
Illinois
| – | -$1.73M | -118,351 | Closed |
|
|
AG
53
Artal Group
Luxembourg
| – | -$1.46M | -100,000 | Closed |
|
|
SSA
54
Schonfeld Strategic Advisors
New York
| – | -$805K | -55,000 | Closed |
|
55
Blackstone Inc
New York
| – | -$146K | -10,000 | Closed |
|
|
DCM
56
DAFNA Capital Management
Los Angeles,
California
| – | -$92K | -6,265 | Closed |
|
|
TRCT
57
Tower Research Capital (TRC)
New York
| – | -$16K | -1,072 | Closed |
|
|
CCA
58
Catalyst Capital Advisors
Huntington,
New York
| – | -$7K | -450 | Closed |
|